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Background
Immune editing is a major mechanism used by tumors to
promote its survival. We have reported previously the pre-
sence of a novel phenotype of immunosuppressive mono-
cytes (CD14+HLA-DRlow/neg) in a number of cancers.
Increased presence of these cells was associated with
decreased treatment response and OS. We have demon-
strated that certain tumor cells can convert normal CD14
+HLA-DR+ monocytes to CD14+HLA-DRlow/neg pheno-
type in an IL-10 independent and a tumor specific way.
These CD14+HLA-DRlow/neg monocytes, in turn, protect
tumors from cytotoxic killing from chemotherapy. Here
we report up-regulation of heat shock protein-27 (HSP27)
as one mechanism mediating this effect.
Method
Monocytes from healthy donors were co-cultured with
lymphoma cell lines (OCI-Ly3, Jeko-1, and Granta-519)
with or without Doxorubicin (DOX). Cultured cells were
assessed for phenotype, viability and proliferation by flow
cytometry. Lymphoma cells were isolated with anti-CD19
immunomagnetic beads and assayed by immunoblot for
expressions of proteins regulating apoptosis. HSP27 levels
in human plasma were measured by ELISA.
Results
DOX incubation induced apoptosis and decreased viability
of all three cell lines; and co-culture with monocytes
improved the lymphoma cell survival (for example,
untreated Granta-519 had a 2.1 ± 0.45 fold expansion, that
was reduced to 0.39 ± 0.12 when treated with DOX and
0.81 ± 0.27 after co-culture with monocytes with DOX.
p < 0.05, n = 11.) Co-culture with monocytes induced
increased HSP27 expression in lymphoma cells. HSP27
levels were further increased in co-culture with monocytes
and DOX, with corresponding decrease in cleaved
Caspase-3 levels. As tumor cells can secrete HSP27, we
found detectable levels of HSP27 in plasma of lymphoma
patients. Increased HSP27 in plasma correlated with
increased proportion of CD14+HLA-DRlow/neg monocytes
in blood.
Conclusions
We have found that monocytes may promote lymphoma
resistance to DOX killing by inducing increased HSP27. In
turn, HSP27 from lymphoma patients may induce
immune suppressive phenotype in monocytes. Together,
this data demonstrates an active cross talk between mono-
cytes and lymphoma resulting in multiple mechanisms of
tumor resistance to chemo-immunotherapy.
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